Novartis Ag

Ciba-geigy Corporation

The Scripps Research Institute

Irm LLC

Euroscreen S.a.

Silvio Roggo

Robert Mah

David Jonathan Glass

Marc Gerspacher

Simone Bonazzi

Andrew William Patterson

Andreas Von Sprecher

Tea Shavlakadze

Walter Schilling

Silvio Ofner

Siem J Veenstra

Manuel Mihalic

Michael Connolly

Stefan Stutz

Yves Auberson

Claudia Betschart

Weijun Shen

Carsten Spanka

Marie-Odile Roy

Wei Li

Francois Gessier

Andreas Katopodis

Sebastien Hannedouche

Birgit Uta Baumgarten

Rocco Falchetto

Michael D Connolly

Klaus Peter Seuwen

Patrik Zueger

Richard Knochenmuss

Andreas Sailer

Juan Zhang

Sophie Noel

Yu Chen

Charles Y Cho

Klaus Seuwen

François Gessier

Sébastien Hannedouche

Birgit Baumgarten

Sophie Noël

The disclosure provides 32-deoxo-rapamycin derivatives of Formula (I), or a pharmaceutically acceptable salt thereof, pharmaceutical compositions and pharmaceutical combinations comprising a compound of Formula (I), and methods of making same. Also provided herein are methods of using a compound of Formula (I) or a pharmaceutically acceptable salt thereof for treating the diseases and disorders described herein.

Rapamycin derivatives

The disclosure relates to compounds of formula (I) and pharmaceutically acceptable salts, and compositions thereof, wherein the substituents are as defined herein. Also provided are methods of making compounds of formula (I), and methods involving the compounds or compositions for treating disorders and diseases described herein.

The present invention relates to modulators of the interaction between Epstein-Barr Virus induced receptor-2 (EBi2) and cholest-5-ene-3b,7b,25-triol (7,25-dihydroxycholesterol) ('7,25DHC') and/or cholest-5-ene-3b, 7b-diol (7-hydroxycholesterol) ('7HC'). The modulator maybe a small chemical molecule, antibody or other therapeutic protein. Methods of medical treatment and methods of identifying modulators are also described.

Methods of identifying a modulator that inhibits the binding between Epstein-Barr virus induced receptor 2 and cholesterol derived ligands

Acylaminoalkenylene-amide derivatives as NK1 and NK2 antagonists

1-aryl-2-acylamino-ethane compounds and their use as neurokinin

Compounds of formula I ##STR1## wherein rings A and B are as defined in the specification, have valuable pharmacological properties and are particularly effective as NK1 antagonists and substance P antagonists. Said compounds are prepared in a manner known per se.

Chromone Derivatives

Growing community of inventors

Nuttenz, Switzerland

Silvio Roggo